K+ channels as targets for specific immunomodulation

Trends in Pharmacological Sciences

Volumn 25, Issue 5, 2004, Pages 280-289

  Chandy, K George ^a   Wulff, Heike ^b   Beeton, Christine ^a   Pennington, Michael ^c   Gutman, George A ^a   Cahalan, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Bachem Holding AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 1,4 DIHYDRO 4 PENTYLIMINOQUINOLINE; 4 BENZHYDRYLOXYMETHYL 1 [3 (4 METHOXYPHENYL)PROPYL]PIPERIDINE; 4 PHENYL 4H PYRAN; BERBERINE; CAFFEINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CETIEDIL; CHLORZOXAZONE; CLOTRIMAZOLE; DENDROTOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ECONAZOLE; INDAN DERIVATIVE; KETAZOCINE; MARGATOXIN; NIFEDIPINE; NITRENDIPINE; NOXIUSTOXIN; PHENCYCLIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PYRAN DERIVATIVE; QUININE; RESINIFERATOXIN; RILUZOLE; STICHODACTYLA HELIANTHUS TOXIN; SULFIMIDE BENZAMIDOINDANE; TETRAPHENYLPORPHYRIN; THEOPHYLLINE; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VOLTAGE GATED POTASSIUM CHANNEL; WIN 173173; ZOXAZOLAMINE;

CELL DIFFERENTIATION; DISEASE COURSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MEMORY CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; HUMANS; LYMPHOCYTES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; T-LYMPHOCYTES;

EID: 2142700028     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.03.010     Document Type: Review

References (83)

1. + fluxes in rat thymocytes stimulated by concanavalin A. J. Cell. Physiol. 89:1976;267-276
2. + channels in human T lymphocytes: a role in mitogenesis? Nature. 307:1984;465-468
3. + channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature. 307:1984;468-471
4. Fukushima Y., et al. Potassium current in clonal cytotoxic T lymphocytes from the mouse. J. Physiol. 351:1984;645-656
5. Chandy K.G., et al. Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med. 160:1984;369-385
6. + channels in human and murine T lymphocytes. J. Gen. Physiol. 93:1989;1061-1074
7. Chandy K.G., et al. Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon. 39:2001;1269-1276
8. Grissmer S., et al. Expression and chromosomal localization of a lymphocyte K+ channel gene. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9411-9415
9. Douglass J., et al. Characterization and functional expression of a rat genomic DNA clone encoding a lymphocyte potassium channel. J. Immunol. 144:1990;4841-4850
10. + channels in human leukemic T cells. J. Gen. Physiol. 99:1992;63-84
11. + channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10094-10098
12. Grissmer S., et al. Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J. Gen. Physiol. 102:1993;601-630
13. Logsdon N.J., et al. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol. Chem. 272:1997;32723-32726
14. Fanger C.M., et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J. Biol. Chem. 274:1999;5746-5754
15. Wulff H., et al. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Dev. 6:2003;640-647
16. Panyi G., et al. Colocalization and nonrandom distribution of the Kv1.3 potassium channel and CD3 molecules in the plasma membrane of human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2592-2597
17. + channel in T lymphocytes upon Fas stimulation. J. Biol. Chem. 271:1996;20465-20469
18. Gulbins E., et al. Ceramide-induced inhibition of T lymphocyte voltage-gated potassium channel is mediated by tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 94:1997;7661-7666
19. Hanada T., et al. Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes. J. Biol. Chem. 272:1997;26899-26904
20. Gong J., et al. Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2. Science. 285:1999;1565-1569
21. Cayabyab F., et al. Suppression of the rat microglia Kv1.3 current by src-family tyrosine kinases and oxygen/glucose deprivation. Eur. J. Neurosci. 12:2000;1949-1960
22. Cahalan M.D., et al. Molecular properties and physiological roles of ion channels in the immune system. J. Clin. Immunol. 21:2001;235-252
23. Jugloff D.G., et al. Internalization of the Kv1.4 potassium channel is suppressed by clustering interactions with PSD-95. J. Biol. Chem. 275:2000;1357-1364
24. Panyi G., et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc. Natl. Acad. Sci. U. S. A. 101:2004;1285-1290
25. + and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J. Exp. Med. 191:2000;1167-1176
26. Partiseti M., et al. The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. J. Biol. Chem. 269:1994;32327-32335
27. Feske S., et al. Gene regulation mediated by calcium signals in T lymphocytes. Nat. Immunol. 2:2001;316-324
28. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19:2001;497-521
29. Price M., et al. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 86:1989;10171-10175
30. Lin C.S., et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177:1993;637-645
31. + channel. J. Biol. Chem. 266:1991;3668-3674
32. Pennington M., et al. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res. 46:1995;354-358
33. 22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 273:1998;32697-32707
34. Tudor J.E., et al. Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat. Struct. Biol. 3:1996;317-320
35. Garcia-Calvo M., et al. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J. Biol. Chem. 268:1993;18866-18874
36. Koo G.C., et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158:1997;5120-5128
37. + channels. Eur. J. Biochem. 242:1996;491-498
38. 2+-activated potassium channel. Mol. Pharmacol. 63:2003;409-418
39. Blanc E., et al. Solution structure of maurotoxin, a scorpion toxin from scorpio maurus, with high affinity for voltage-gated potassium channels. Proteins. 29:1997;321-333
40. Beeton C., et al. A novel fluorescent toxin to detect and investigate Kv1.3-channel up-regulation in chronically activated T lymphocytes. J. Biol. Chem. 278:2003;9928-9937
41. Freudenthaler G., et al. Ultrasensitive pharmacological characterisation of the voltage-gated potassium channel K(V)1.3 studied by single-molecule fluorescence microscopy. Histochem. Cell Biol. 117:2002;197-202
42. Nguyen A., et al. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol. Pharmacol. 50:1996;1672-1679
43. Hanson D.C., et al. UK-78, 282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br. J. Pharmacol. 126:1999;1707-1716
44. Wanner S., et al. WIN 17317-3, a new high-affinity probe for voltage-gated sodium channels. Biochemistry. 38:1999;11137-11146
45. Gradl S.N., et al. Protein surface recognition by rational design: nanomolar ligands for potassium channels. J. Am. Chem. Soc. 125:2003;12668-12669
46. Goetz M.A., et al. Potent Nor-triterpenoid blockers of the voltage-gated potassium channel Kv1.3 from Spachea correae. Tetrahedron Lett. 39:1998;2895-2898
47. Felix J.P., et al. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 38:1999;4922-4930
48. Koo G.C., et al. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell. Immunol. 197:1999;99-107
49. Schmalhofer W.A., et al. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry. 41:2002;7781-7794
50. Wojtulewski J.A., et al. Clotrimazole in rheumatoid arthritis. Ann. Rheum. Dis. 39:1980;469-472
51. + channel, IKCa1: A potential immunosuppressant. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8151-8156
52. Stocker J.W., et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 101:2003;2412-2418
53. Wulff H., et al. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel IKCa1. J. Biol. Chem. 276:2001;32040-32045
54. Kohler R., et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 108:2003;1119-1125
55. Urbahns K., et al. 4-Phenyl-4H-pyrans as IKCa channel blockers. Bioorg. Med. Chem. Lett. 13:2003;2637-2639
56. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111:2003;1703-1713
57. Sallusto F., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;708-712
58. Ghanshani S., et al. Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J. Biol. Chem. 275:2000;37137-37149
59. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13942-13947
60. + channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 37:2001;1315-1322
61. Davies A.M., et al. Potassium channel KV 1 subunit expression and function in human detrusor muscle. J. Urol. 167:2002;1881-1886
62. Grunnet M., et al. The voltage-gated potassium channel subunit, Kv1.3, is expressed in epithelia. Biochim. Biophys. Acta. 1616:2003;85-94
63. Valverde P., et al. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J. Bone Miner. Res. 19:2004;155-164
64. Hess S.D., et al. Calcium oscillations in human T and natural killer cells depend upon membrane potential and calcium influx. J. Immunol. 150:1993;2620-2633
65. + channels in human leukemic T cells. J. Gen. Physiol. 99:1992;63-84
66. Partiseti M., et al. Differential regulation of voltage- and calcium-activated potassium channels in human B lymphocytes. J. Immunol. 148:1992;3361-3368
67. Pillozzi S., et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia. 16:2002;1791-1798
68. Gray P.T., et al. Ion channels in rabbit cultured fibroblasts. Proc. R. Soc. Lond. B. Biol. Sci. 227:1986;1-16
69. Amigorena S., et al. Ion channels and B cell mitogenesis. Mol. Immunol. 27:1990;1259-1268
70. Ramsdell J.S. Voltage-dependent calcium channels regulate GH4 pituitary cell proliferation at two stages of the cell cycle. J. Cell. Physiol. 146:1991;197-206
71. + current in small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 257:1991;184-191
72. Pappone P.A., Ortiz-Miranda S.I. Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am. J. Physiol. 264:1993;C1014-C1019
73. + current during the differentiation of ML-1 human myeloblastic leukemia cells. J. Membr. Biol. 132:1993;267-274
74. Skryma R.N., et al. Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate. 33:1997;112-122
75. + channel in malignant astrocytoma cell lines. J. Neurosci. Res. 48:1997;122-127
76. +) channels. EMBO J. 18:1999;5540-5547
77. 2+ influx in carcinoma cells of colon cancer. Life Sci. 65:1999;55-62
78. + channel expression. Eur. J. Pharmacol. 444:2002;115-121
79. + channels in neoplastic hematopoietic cells. J. Biol. Chem. 277:2002;18528-18534
80. Neylon C.B. Potassium channels and vascular proliferation. Vascul. Pharmacol. 38:2002;35-41
81. + channels inhibits adhesion and proliferation of hepatocarcinoma cells. Int. J. Mol. Med. 11:2003;261-266
82. Vennekamp, J., et al. Kv1.3 blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol. Pharm. (in press).
83. + effector memory cells relative to central memory cells. Blood (in press).